Member Info for Bella6532

IPancreatic Cancer patients already in our trial(s)

Abstract

Background: AVA6000 is a peptide drug conjugate, consisting of a peptide moiety that is specifically cleaved by FAP in the TME that is bound to doxorubicin. FAP is selectively overexpressed in many solid tumors. The peptide moiety linker (pre|CISIONTM) prevents cellular entry of doxorubicin unless cleaved by FAP, thus enabling targeted delivery of doxorubicin to tumors.

Design: The safety, PK and preliminary efficacy of AVA6000 was studied in a first-in-man, multicenter dose escalation phase I trial. AVA6000 was administered intravenously q3w using a standard 3+3 design in patients with locally advanced or metastatic solid tumors reported to be FAP-positive. PK (AUC) based dosing was implemented to calculate maximum cycles of AVA6000 with the cumulative limit of 550 mg/m2.

Results: Forty patients (median age 65 years, range 30-79), with median 3 prior lines of therapy (range, 0-7) received escalating AVA6000 doses from 80mg/m2 (51 mg/m2 doxorubicin; molar equivalent, 0.675) to 385 mg/m2 (260 mg/m2 doxorubicin equivalent). Tumor types included soft tissue sarcoma (30%), colorectal cancer (27.5%), pancreatic cancer (20%), cancers of the biliary tract (7.5%).

And once detected...

'The high lethality of this disease is a consequence of the late detection of this tumor.2 In fact, most patients are diagnosed with locally advanced or metastatic disease, which renders them ineligible for surgery.'...so, what to do?

Ah Ha...we need a high dose PreCision warehead which can seek out all those nasty cancer cells wherever they miggt be lurking and zap the cr*p out of them quickly with the patient feeling pretty much no side effects and no need for the knife.

Mmmm! Does anyone know where we might get such a product?

Seriously...this is for me where Our Precision warheads will come into their own...late diagnosis.

Agree Timster...a reveal...why are we going to be soooo happy when she discloses what the new pipeline is going to be and with timescales. So how can she put timescales on a pipeline without there being a discussion about finance.

Robinhd...You might want to check your trade was actually actioned...

Very much US style motivational blurb.

So many changes at the top recently can be disruptive and unsettling for a workforce and it appears to be her way of offering reassurance and to motivate at the same time....patting them on their backs way up high and all that good stuff.

The Avacta team is not in a bubble and they too can read the RNS's/press reports and listern to the webinars etc put out by the company. Talk of possibly divesting DX and the company having to raise funds etc etc let alone any mention of T/O they might come across.

Perhaps a BP/investor has put their cards on the table and said they will do a deal for bla bla based on the 2W trial data and/ or FDA approval...or perhaps a BP or major investor was the one calling for the 2W trial.

Can't believe how many scientists/Phds we seem to accrue on here. CC obviously wasn't the best pick...some on here, particularly those who spend all their time in a green box, appear to have far much more knowledge and perhaps we should send a bunch of their posts which I'm sure CC and her colleagues will find most interesting on many levels. Never know it could result in a job offer or...

'At Avid, a wholly-owned subsidiary of Eli Lilly and Company, our mission is to discover, develop, and deliver diagnostic solutions that improve global health by accelerating the development of new medicines.

image-card 0000 Lilly.com-Avid-shutterstock 1281289246

Early Diagnosis Enables Early Intervention

Avid’s diagnostic solutions aid in early diagnosis, monitor the treatment effect of therapeutics and help understand disease pathology better. Avid is leveraging the power of diagnostics to transform patient outcomes.

Our diagnostic portfolio includes two PET imaging agents approved by the U.S. Food and Drug Administration: Amyvid, approved in 2012, and Tauvid, approved in 2020.

Avid is committed to accelerating the next generation of diagnostic tools to understand and unlock the potential of emerging science, enable the discovery of new medicines, and advance care for patients with unmet needs'

What does Avid mean on a PET scan...???

Join the dots...

Https://www.fiercebiotech.com/biotech/lilly-signs-140m-upfront-partnership-radionectics-latest-radiopharma-play

'Affimer® technology

Next-generation biotherapeutic class to surpass

the limitations of antibody cancer therapies'

A pretty bold statement IMO.

Do you realise how difficult it must be to crack the antibody brigade...

Q = latin reference short for quisque (every, everything etc)

OandW...I suspect he's got his eyes on you...haha...

Https://sofie.com/2022/02/22/could-fibroblast-activation-protein-fap-specific-radioligands-be-considered-as-pan-tumor-agents/

Based on LLY's Point purchase...what would they gain from the new Avacta trial scanner data???

Oops...was no we...grrrr!

1 August 1.12m traded (High = 71.0)

2 August 2.14m Traded

5 August 4.23m Traded (Low = 52.10)

6 August 1.80m Traded

7 August 1.65m Traded

8 August 1.15m Traded so far and SP now back to 69.00

We this a dip to simply fill a large order at a low ball price? or good old Hedging boys...

This game is all about making money...afraid many lose money and get very upset.

Did anyone invest in a company to lose money...No.

If Avacta had any doubts whatsoever regarding the potential for AVA6000 and pipeline they wojld not be talking up the possible disposal of DX.